Form D · Biotechnology

Tolerion, Inc.

South San Francisco, CA · CIK 0001733538

Offering snapshot reported Feb 10, 2020 · SEC filing

Reported sold
$23M
Offering amount: $29.8M
Investors reported
12
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 28, 2017
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 10, 2020Initial$23,005,089No comparison12SEC filing
Jan 31, 2020Initial$19,999,998No comparison4SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$891K (estimated)
Finders' fees
$0
Form D file number
021-360181
Series B Preferred Stock and the underlying Common Stock issuable upon conversion thereof.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
CIM Securities, LLC120852

Source: Form D, filed Feb 10, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Graeme Curie Executive
John Donovan Director, Executive
Alexander Fleming Executive
Scott Geyer Executive
Randolph Johnson Executive
Paul Manning Director
Sean Stalfort Director
Lawrence Steinman Director
James Stutz Executive
Stephen Zachary Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
131 Oyster Point Blvd. Suite 400
South San Francisco, CA, 94080